Levofolinic acid<unk>  is given<unk> lowing methotrexate as part of a total chemotherapeutic plan, where it may protect against bone marrow suppression or gastrointestinal mucosa inflammation. No apparent effect is seen on pre-existing methotrexate-induced nephrotoxicity.<unk>  can be taken as a pill (orally) or injected into a vein (intravenously) or muscle (intramuscularly). While not specifically an antidote for methotrexate,<unk>  may also be useful in the treatment of acute methotrexate overdose. Different dosing protocols are used, but<unk>  should be redosed until the methotrexate level is less than 5 x 10−8 M. Additionally,<unk>  is sometimes used to reduce the side effects of methotrexate in rheumatoid arthritis patients. This includes reductions in nausea, abdominal pain, abnormal liver blood tests, and mouth sores.<unk>  is also used in combination with the chemotherapy agent 5-fluorouracil in treating colon cancer. In this case,<unk>  is not used for "rescue" purposes; rather, it enhances the effect of 5-fluorouracil by inhibiting thymidylate synthase.<unk>  is also sometimes used to prevent toxic effects of high doses of antimicrobial dihydrofolate reductase inhibitors such as trimethoprim and pyrimethamine. It may be prescribed in the treatment of toxoplasmosis retinitis, in combination with the<unk> ic acid antagonists pyrimethamine and sulfadiazine.<unk>  is also used in the treatment of cerebral<unk> ate deficiency, a syndrome in which the use of<unk> ic acid cannot normalize cerebrospinal fluid levels of 5-MTHF.
Folinic acid
Tienilic acid
Kaurenoic acid
Alpha-Zearalenol
Ioxaglic acid
Beta-Zearalenol
Sakacin
Ellagic acid